GO
Loading...

Supreme Court Declines Review of Amgen Patent Dispute

The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.

In the latest in a series of major patent cases, the high court declined to review whether a specialized patent appeals court in Washington, D.C., can scrap key patent interpretations made by district court judges during an appeal.

The case is part of Amgen's long-standing patent battle to prevent two other drugmakers from selling a product that would compete with its widely used Epogen anemia treatment.

Amgen in 1997 sued the drugmakers, Hoechst Marion Roussel and Transkaryotic Therapies, in U.S. District Court for the District of Massachusetts, alleging their planned product infringed five Amgen patents. Hoechst, after a merger, is now part of Paris-based Sanofi-Aventis. Transkaryotic has since been acquired by Shire Pharmaceuticals Group of Britain.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video

  • In this clip taken from a body camera worn by Rialto police, a man who had been acting suspiciously assaults an officer. Police have been using cameras for 3 years and seen an 80 percent reduction in complaints, as well as a 60 percent drop in use of force.

  • It's a tough time to be a police officer, and Rialto police Sgt. Josh Lindsay, who's been a cop for over 20 years, wonders if he'd recommend the job now. However, he has no regrets.

  • Federal Reserve Chair Janet Yellen, discusses whether the committee is concerned over economic developments in Russia.